Cochrane · systematic review · CD009266
Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer
Kunath, F, Grobe, HR, Rücker, G, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 6 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Non‐steroidal antiandrogen monotherapy versus LHRH agonists or surgical castration monotherapy for advanced prostate cancer
Population: men with advanced prostate cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy | HR 1.24 [1.05, 1.48] | 6 studies · 2712 participants | Moderate Downgraded: risk of bias, inconsistency |
Clinical progression Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy | RR 1.26 [1.08, 1.45] | 6 studies · 2373 participants | Moderate Downgraded: risk of bias, inconsistency |
Treatment failure Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy | RR 1.27 [1.05, 1.52] | 5 studies · 1845 participants | Moderate Downgraded: risk of bias, inconsistency |
Breast pain Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy | RR 22.97 [14.79, 35.67] | 8 studies · 2670 participants | Moderate Downgraded: risk of bias |
Gynaecomastia Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy | RR 8.43 [3.19, 22.28] | 9 studies · 2774 participants | Moderate Downgraded: risk of bias, inconsistency |
Hot flashes Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy | RR 0.23 [0.19, 0.27] | 9 studies · 2774 participants | Moderate Downgraded: risk of bias |